Merck's Oral PCSK9 Inhibitor MK-0616 Granted Clinical Trial Approval in China for Hypercholesterolemia and ASCVD

　　【Pharmaceutical Network Industry DynamicsIn recent years, innovative drugs have been driving the rapid expansion of China's pharmaceutical market. In response to this changing landscape, multinational pharmaceutical companies are increasingly accelerating their efforts to introduce more new drugs into the Chinese market.
 

On November 15, the website of the Center for Drug Evaluation (CDE) under the National Medical Products Administration (NMPA) disclosed that the MK-0616 capsule, submitted by MSD, had received tacit approval for clinical trials. It is intended to be developed for the treatment of hypercholesterolemia and atherosclerotic cardiovascular disease. Public information shows that MK-0616 is a new type of cholesterol-lowering drug, an oral PCSK9 inhibitor, which has already entered phase 2 clinical research overseas. Results from phase 1 clinical trials showed that when MK-0616 was used in combination with statins, it could reduce low-density lipoprotein cholesterol (LDL-C) levels in the blood by 65%.
 

According to reports, in recent years, MSD has been actively expanding its market in China, while continuously bringing more best-in-class and innovative drugs and therapies. In addition to the MK-0616 capsule, on May 13 this year, the NMPA website announced that MSD's antiviral drug letermovir injection had been approved for marketing. The product is reported to have a novel anti-CMV effect by inhibiting the activity of the cytomegalovirus terminase complex, preventing the processing and packaging of viral DNA, thereby exerting its antiviral function. Notably, the tablet form of this drug was already approved in China in January this year for the prophylactic treatment of cytomegalovirus...
 

China has always been a significant market in the global strategies of multinational pharmaceutical companies. Statistics show that in 2021, China's pharmaceutical industry achieved a revenue of 3,370.75 billion RMB, with growth reaching a five-year high. Attracted by the vast market, many multinational pharmaceutical enterprises have stated that the strategic importance of the Chinese market in their global operations will remain stable over the next three to five years. Meanwhile, an increasing number of fast-growing pharmaceutical companies are gearing up to introduce more innovative products into the Chinese market.
 

For example, during this year's CIIE, many multinational pharmaceutical companies showcased a large number of new drugs. Among them, AstraZeneca exhibited its first product in the rare disease field, Eculizumab Injection. This is a prescription drug that has been approved for use in China for the treatment of adults and children with paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS).
 

Teva Brought Anaitan, Which Is Used to Treat Huntington's Disease, Commonly Known as "Chorea." Chorea is a Rare Autosomal Dominant Hereditary Neurodegenerative Disease, and Most Patients Exhibit Involuntary Choreiform Movements. Currently, Anaitan Has Been Approved for Marketing in China Through the Priority Review and Approval Process and Has Been Included in the Medical Insurance Catalog.
 

Sanofi brought several new rare disease drugs to the CIIE, including Cablivi, the world’s first approved nanobody drug, which is also the first targeted treatment for acquired thrombotic thrombocytopenic purpura (aTTP). Another drug showcased was Nexviazyme, a next-generation enzyme replacement therapy (ERT) for Pompe disease. This drug has been granted "Breakthrough Therapy" designation by the FDA and is expected to significantly improve respiratory function and motor ability in patients with Pompe disease…
 

Currently, many multinational pharmaceutical companies are exploring innovative R&D, win-win cooperation, and digital intelligence as ways to seek more opportunities in the Chinese market. Therefore, news of multinational pharmaceutical companies setting up factories and establishing R&D centers in mainland China has been frequently emerging in recent years. The industry believes this fully demonstrates their emphasis on and optimism about the Chinese market, which will also bring more treatment options to patients in China in the future.
 

Disclaimer: In any case, the information or opinions expressed in this article do not constitute investment advice to any person.